October 24, 2024

Awards for young scientists from Heidelberg

Awards for young scientists from Heidelberg

Ruprecht Karls Prizes and Fritz Grunebaum Prize to be awarded on October 25

The Heidelberg University Foundation honors young academics with the Ruprecht Karls Prizes for their outstanding scientific publications. The awards go to five doctoral students from various disciplines. The Fritz Grunebaum Prize will also be awarded during the festive event in the auditorium of the Old University. The Foundation invites you to the award ceremony with University Rector Prof. Dr. Frauke Melchior on Friday, October 25, 2024.

The winners of the Ruprecht Karls Prizes are Dr. Lynton Ardizzone (Physics), Dr. Ioannis Sarropoulos (Biosciences), Dr. Friederike Juliane Ihssen (Physics), Dr. Norina Christa Ullmann (Theology) and Dr. Philipp Mai (Political Science). They each receive prize money of 3,000 euros. The Fritz Grunebaum Prize of the Heidelberg University Foundation, which also comes with prize money of 3,000 euros, is awarded for outstanding work in the field of economics or business law. This year’s winner is Dr. Nina Benz (Law).

The Rector of Heidelberg University and Dr. Monika Vierheilig, Chairwoman of the Heidelberg University Foundation, will kick off the ceremony. The bioscientist Prof. Dr. Thomas Rausch and the theologian Prof. Dr. Thorsten Moos – members of the jury for the awards – will introduce the prizewinners and pay tribute to their work. The award ceremony will also mark the start of a two-day meeting to which – following the first networking event of this kind in 2019 – all award winners from previous years are once again invited. The program offers plenty of space for academic, professional and personal discussions.

Since 1990, the Heidelberg University Foundation has awarded these two prizes to young academics at Heidelberg University who have achieved outstanding research results. As a rule, the six best doctoral theses are honored each year. The multi-stage, university-wide selection process takes into account academic first theses from all subjects. To date, more than 180 people have been awarded these prizes.

Original News

Our latest News

discover more
New Publication from Sciomics GmbH: Fimepinostat Promotes Apoptosis and Decreases Cytokine Secretion in NF2-Related Human Schwannoma Cells

New Publication from Sciomics GmbH: Fimepinostat Promotes Apoptosis and Decreases Cytokine Secretion in NF2-Related Human Schwannoma Cells

Nagel, A.; Hass, E.W.; Hayes, H.; Huelbes, L.; Oliveira, S.; Hardin, H.M.; Marasigan, M.; Nisenbaum, E.; Misztal, C.; Telischi, F.F.; et al. Fimepinostat Promotes Apoptosis and Decreases Cytokine Secretion in NF2-Related Human Schwannoma Cells. Int. J. Mol. Sci. 2026, 27, 2636. https://doi.org/10.3390/ijms27062636 https://www.mdpi.com/1422-0067/27/6/2636 Simple Summary This study focuses on the action of fimepinostat, a dual histone deacetylase (HDAC)/phosphosphoinositide-3 kinase […]

Fraunhofer IPA wins the “euRobotics Technology Transfer Award” together with Trumpf and Lorch

Fraunhofer IPA wins the “euRobotics Technology Transfer Award” together with Trumpf and Lorch

Technology transfer that works: At the “European Robotics Forum” (ERF) in late March, the trio of applicants won the prestigious award. The award recognizes research that has found its way into industrial applications. The application focused on a “no-code” solution that allows companies to deploy cobots without specialized knowledge or significant welding effort, even for […]

Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria

Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria

Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria Paris and Tarrytown, NY, April 13, 2026. The European Commission has approved Dupixent (dupilumab) for the treatment of moderate-to-severe chronic spontaneous urticaria (CSU) in children aged two to 11 years with inadequate response to histamine-1 […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp